Cargando…
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells
Cancer is a leading cause of death worldwide, and while great advances have been made particularly in chemotherapy, many types of cancer still present a dismal prognosis. In the case of glioma, temozolomide (TMZ) is the main option for treatment, but it has limited success due to drug resistance. Wh...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217002/ https://www.ncbi.nlm.nih.gov/pubmed/27344172 http://dx.doi.org/10.18632/oncotarget.10129 |